A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Part of paid clinical trials in Aurora, Colorado.

Sponsor
Anthos Therapeutics, Inc.
Study ID
NCT05171049
Phase
PHASE3
Status
Terminated

Conditions

  • Deep Venous Thrombosis
  • Pulmonary Embolism
  • Venous Thromboembolism

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Abelacimab — BIOLOGICAL
    Abelacimab 150 mg
  • Apixaban — DRUG
    Apixaban 10 mg followed by 5 mg

Study Details

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

Key Dates

Start date
May 5, 2022
Status verified
Feb 2026
Primary completion
Feb 4, 2026
Completion
Feb 4, 2026

Study Design

Enrollment
1,150 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Abelacimab
    Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
  • Active Comparator: Apixaban
    Apixaban administered orally twice a day

Primary Outcome Measure

Time to first event of centrally adjudicated VTE recurrence [ Time Frame: Up to 6 months ]

Locations (23)

FacilityCityStateZIPSite coordinators
University of Colorado Anschutz Medical CampusAuroraColorado80045-
VA Connecticut Healthcare SystemWest HavenConnecticut06516-5907-
Washington DC VAMCWashington D.C.District of Columbia20422-
University of Miami HealthMiamiFlorida33136-
NorthShore University Health SystemEvanstonIllinois60201-
University of Kentucky, Markey Cancer CenterLexingtonKentucky40536-0093-
Beth Israel Deaconess Medical CenterBostonMassachusetts02215-5400-
Brigham and Women's HospitalBostonMassachusetts02115-
Henry Ford Health SystemDetroitMichigan48202-
Washington UniversitySt LouisMissouri63110-
Memorial Sloan Kettering Cancer Center-MiddletownMiddletownNew Jersey07748-
Memorial Sloan Kettering Cancer Center-CommackCommackNew York11725-
Memorial Sloan Kettering Cancer Center-West HarrisonHarrisonNew York10604-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10021-0005-
Lipson Cancer InstituteRochesterNew York14621-
Duke University Medical CenterDurhamNorth Carolina27710-
Cleveland Clinic FoundationClevelandOhio44195-
University of Oklahoma Health Sciences CenterOklahoma CityOklahoma73104-
University of Pennsylvania - Penn Blood Disorders CenterPhiladelphiaPennsylvania19104-
MD Anderson Cancer CenterHoustonTexas77030-
University of Texas Mays Cancer CenterSan AntonioTexas78229-
Gundersen Health SystemLa CrosseWisconsin54601-
Blood Center of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Aurora, CO

By research site
University of Colorado Anschutz Medical Campus· Aurora, COVA Connecticut Healthcare System· West Haven, CTWashington DC VAMC· Washington D.C., DCUniversity of Miami Health· Miami, FLNorthShore University Health System· Evanston, ILUniversity of Kentucky, Markey Cancer Center· Lexington, KY

Related Studies